Scorpius Partners with Biotech Firm to Boost U.S. Biomanufacturing Capabilities

Scorpius Holdings, Inc. (NYSE American: SCPX), an integrated contract development and manufacturing organization (CDMO) specializing in biologics, has announced a strategic partnership with a U.S.-based biotech company. This collaboration aims to expand Scorpius' manufacturing capacity and support more biotech clients, while addressing the critical need for secure, U.S.-based development and manufacturing support for groundbreaking biologics research.

Scorpius' flexible and responsive approach to biomanufacturing enables it to support biotech companies throughout their development journey. By utilizing single-use, disposable technology, Scorpius reduces the risk of contamination and cross-contamination, allowing for quick changeover between batches and minimizing the need for cleaning validation studies. This approach, combined with a modular and multi-product facility design, enables Scorpius to support a wide range of biotech projects and product lifecycles.


The partnership with the U.S.-based biotech company will enable Scorpius to expand its manufacturing capacity, attract new customers, and generate meaningful cash flow. By leveraging its fixed costs and achieving long-term profitability, Scorpius aims to become a leading pure-play CDMO in the biologics space.


This strategic partnership enhances Scorpius' ability to provide flexible, high-quality biologics biomanufacturing services. By working with the biotech company's program management team and transferring a research cell bank (RCB) to Scorpius' state-of-the-art facilities in San Antonio, TX, the partnership will enable Scorpius to support more biotech clients and contribute to the growth of the U.S. biotech industry.

The partnership also addresses the critical need for secure, U.S.-based development and manufacturing support for groundbreaking biologics research. As biotech companies increasingly seek U.S.-based biomanufacturing partners, Scorpius' capabilities in early-stage development, preclinical manufacturing, and cGMP clinical manufacturing for both mammalian and microbial programs position it well to meet this demand.

In conclusion, Scorpius' partnership with the U.S.-based biotech company is a significant step towards boosting U.S. biomanufacturing capabilities. By expanding its manufacturing capacity and enhancing its ability to provide flexible, high-quality biologics biomanufacturing services, Scorpius is well-positioned to support the growth of the U.S. biotech industry and contribute to a sustainable future in the biologics space.